The importance of serum immunoglobulin free light chain assay in AL amyloidosis
Authors:
T. Pika 1; P. Lochman 2; J. Minařík 1; J. Bačovský 1; V. Ščudla 1
Authors‘ workplace:
III. interní klinika – nefrologická, revmatologická, endokrinologická, LF UP a FN Olomouc
1; Oddělení klinické biochemie, FN Olomouc
2
Published in:
Transfuze Hematol. dnes,19, 2013, No. 3, p. 134-138.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Introduction.
Systemic AL amyloidosis is a rare illness in the group of monoclonal gammopathies. The disease is based on extracellular deposition of insoluble fibrils formed by complete monoclonal light immunoglobulin chains or their fragments, produced by clonal plasmocytes. Identification of the plasmocyte clone, or of its protein product – the monoclonal immunoglobulin (MIg) – represents a key aspect of diagnostics and monitoring of AL amyloidosis patients. Serum immunoglobulin free light chain (FLC) assay, routinely performed in the recent years, significantly widened the options for MIg analysis in monoclonal gammopathies. The subject of this report is practical experience with serum immunoglobulin free light chains assay in AL amyloidosis patients.
Patients and Methods.
The patient set comprised 19 patients with biopsy-verified systemic AL amyloidosis. Age median was 62 years of age (48–92 years of age), male to female ratio was 16 : 3, representation of secretion kappa : lambda was 3 : 16. Free light chains serum levels were determined by the FreeLiteTM system. Normal range of serum levels was 3.3–19.4 mg/l for light chain kappa (κ), and 5.7–26.3 mg/l for light chain lambda (λ). Mutual ratio of light chains kappa/lambda (the κ/λ index) was determined by a calculation with normal range 0.26–1.65, in case of renal insufficiency 0.37–3.1.
Results.
MIg serum levels were determined in 12 out of 18 (68%) patients, where the median level was 1.69 g/l (0–9.8 g/l). As for isotypes, there were 4 cases of complete isotype IgG (2x IgG-κ, 2x IgG-λ), 3 cases of IgA-λ, and one patient presented the isotype IgD-λ. Light chains λ only were found in the serum of 4 patients. Protein analysis of urine found excretion of Bence-Jones protein in 11 patients, in all cases in quantity over 200 mg/24 hours, while the presence of complete MIg molecules in the urine (1x IgA-λ, 1x IgG-λ) was additionally determined in 2 patients. Serum immunoglobulin free light chain assay determined abnormal levels in all patients with median value 399 mg/l (54.4–2 385 mg/l), while κ/λ index pathology was determined in 17 (90%) patients. Out of the 17 patients with abnormal FLC levels and concomitant κ/λ index pathology, 16 patients had dFLC levels > 50 mg/l (dFLC = difference between dominant and alternative FLC levels). Therefore, FLC assay enables regular monitoring of the disease in 16 out of 19 (84%) patients.
Conclusion.
Serum immunoglobulin free light chain assay currently represents a key laboratory parameter not only for dia-gnostics and monitoring of the course of the disease, but namely for treatment efficacy evaluation. A combination of standard MIg detection techniques with FLC level assay enables monitoring of a vast majority of AL amyloidosis patients.
Key words:
AL amyloidosis, free light immunoglobulin chains, disease monitoring
Sources
1. Ščudla V, Pika T. Současné možnosti diagnostiky a léčby systémové AL-amyloidózy. Vnitř Lék 2009; 55: 77-87.
2. Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of International Society of Amyloidosis. Amyloid 2010; 17: 101-104.
3. Bird J, Cavenagh J, Hawkins P, et al. Guidelines on the diagnosis and management of AL amyloidosis. Brit J Hematol 2004; 125: 681-700.
4. Gertz MA. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011; 86: 181-186.
5. Sanchorawala V, Blanchard E, Seldin DC, O’Hara C, Skinner M, Wright DG. AL amyloidosis associated with B-cell lymphoproliferative disorders: frequency and treatment outcomes. Am J Hematol 2006; 81: 692-695.
6. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583-596.
7. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 2011; 29: 1924-1933.
8. Bradwell AR. Serum free light chain measurements move to center stage. Clin Chem 2005; 51: 805-807.
9. Katzmann JA, Kyle RA, Benson J et al. Screening panels for detection of monoclonal gammopathies. Clin Chem 2009; 55: 1517-22.
10. Abraham RS, Katzmann JA, Clark RJ, Bradwell AR, Kyle RA, Gertz MA Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003; 119: 274-278.
11. Palladini G, Russo P, Bosoni T, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 2009; 55: 499-504.
12. Akar H, Seldin DC, Magnani B, et al. Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis. Amyloid 2005; 12: 210-215.
13. Dispenzieri A, Kyle RA, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23: 215-224.
14. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005; 79: 319-328.
15. Gertz MA, Merlini G. Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion. Amyloid 2010; 17: 48-49.
16. Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 2012; 26: 2317-2325.
17. Kumar S, Dispenzieri A, Lacy MQ, et al. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol 2011; 86: 251-255.
18. Kumar S, Dispenzieri A, Katzmann JA, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood 2010; 116: 5126-5129.
19. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30: 989-995.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2013 Issue 3
Most read in this issue
- Current treatment of myelofibrosis based on risk stratification of patients
- Lymphomas of gastrointestinal tract – clinico-pathological review
- The importance of serum immunoglobulin free light chain assay in AL amyloidosis
- Plasma cell leukaemia